Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.
Guja C, Kis JT, Haluzík M, Bonnemaire M, Bigot G, Tournay M, Freemantle N, Seufert J. Guja C, et al. Among authors: bigot g. Diabetes Obes Metab. 2023 Jun;25(6):1723-1730. doi: 10.1111/dom.15027. Epub 2023 Mar 21. Diabetes Obes Metab. 2023. PMID: 36810874
Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis.
Haluzík M, Seufert J, Guja C, Bonnemaire M, Bigot G, Tournay M, Kis JT, Freemantle N. Haluzík M, et al. Among authors: bigot g. Diabetes Ther. 2023 Apr;14(4):639-652. doi: 10.1007/s13300-023-01375-8. Epub 2023 Feb 14. Diabetes Ther. 2023. PMID: 36787044 Free PMC article.
Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database.
Müller-Wieland D, Freemantle N, Bonadonna RC, Mauquoi C, Bigot G, Bonnemaire M, Gourdy P, Mauricio D. Müller-Wieland D, et al. Among authors: bigot g. Diabetes Ther. 2023 Feb;14(2):401-413. doi: 10.1007/s13300-022-01356-3. Epub 2023 Jan 4. Diabetes Ther. 2023. PMID: 36596946 Free PMC article.
Distribution and characteristics of newly-defined subgroups of type 2 diabetes in randomised clinical trials: Post hoc cluster assignment analysis of over 12,000 study participants.
Landgraf W, Bigot G, Hess S, Asplund O, Groop L, Ahlqvist E, Käräjämäki A, Owens DR, Frier BM, Bolli GB. Landgraf W, et al. Among authors: bigot g. Diabetes Res Clin Pract. 2022 Aug;190:110012. doi: 10.1016/j.diabres.2022.110012. Epub 2022 Jul 18. Diabetes Res Clin Pract. 2022. PMID: 35863553 Free article.
22 results